Insider Trading January 22, 2026

AZZ Inc. Legal Chief Divests Shares Amid Strong Fiscal Performance

Chief Legal Officer Tara D Mackey sells $353K of AZZ shares following company’s robust Q3 earnings

By Ajmal Hussain AZZ
AZZ Inc. Legal Chief Divests Shares Amid Strong Fiscal Performance
AZZ

Tara D Mackey, Chief Legal Officer at AZZ Inc., sold nearly 2,800 shares valued at approximately $353,000 under a prearranged trading plan. Concurrently, AZZ reported better-than-expected third-quarter financial results for fiscal 2026, highlighting stronger earnings and revenue growth than market forecasts.

Key Points

  • Chief Legal Officer Tara D Mackey sold 2,790 shares valued at approximately $353,000 under a pre-established trading plan, maintaining regulatory compliance.
  • AZZ Inc. posted impressive Q3 fiscal 2026 results, with reported EPS of $1.52 beating the expected $1.49 and record sales of $426 million surpassing the forecasted $419 million.
  • AZZ's performance highlights strong operational execution and resilience, factors that are positively viewed by investors assessing the industrial sector and manufacturing markets.

Tara D Mackey, who holds the position of Chief Legal Officer at AZZ Inc. (NYSE:AZZ), completed a sale of 2,790 shares of the company’s common stock on January 21, 2026. The transaction occurred at a weighted average price between $126.03 and $127.21 per share, culminating in a total sale value of $353,313.

After this disposition, Mackey retains direct ownership of 25,296 AZZ shares. This share sale was conducted within the parameters of a Rule 10b5-1 trading plan that had been established previously on August 14, 2025, allowing for systematic trading without the influence of non-public information.

Meanwhile, AZZ reported its financial results for the third quarter of fiscal year 2026, with performance surpassing analyst expectations. The company's reported earnings per share (EPS) stood at $1.52, exceeding the anticipated figure of $1.49. Additionally, AZZ achieved record quarterly sales amounting to $426 million, outpacing the forecasted $419 million.

These achievements underscore AZZ's capacity to exceed market predictions and reveal resilience in its business operations. The strong earnings and sales results are significant indicators of the company’s fiscal health and operational momentum, factors closely monitored by investors and analysts alike.

Investor response to these developments has been generally positive, reflecting confidence in AZZ’s continued growth trajectory. The combination of executive insider selling under a scheduled plan and positive financial disclosures highlights a balanced narrative often seen in companies aiming to maintain transparency and compliance while capitalizing on favorable business conditions.

Risks

  • The insider sale follows a prearranged plan, but insider selling can sometimes prompt market scrutiny regarding executive confidence in near-term company prospects, affecting investor sentiment in the industrial sector.
  • Despite recent strong quarterly performance, fluctuations in market demand or operational challenges could impact future earnings and revenue, posing uncertainties for stakeholders focused on manufacturing and industrial markets.
  • The reliance on exceeding analyst expectations places ongoing pressure on AZZ to sustain performance, which may be difficult given economic or sector-specific headwinds.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026